Drug Type Small molecule drug |
Synonyms 3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid, 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid, 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid + [21] |
Target |
Action inhibitors |
Mechanism NKCC1 inhibitors(Solute carrier family 12 member 2 inhibitors), NKCC2 inhibitors(Sodium-(potassium)-chloride cotransporter 2 inhibitors), SLC12A4 inhibitors(solute carrier family 12 member 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (08 Apr 1976), |
Regulation- |
Molecular FormulaC17H20N2O5S |
InChIKeyMAEIEVLCKWDQJH-UHFFFAOYSA-N |
CAS Registry28395-03-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00247 | Bumetanide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Heart Failure | Canada | 31 Dec 1993 | |
Acute Kidney Injury | China | 01 Jan 1982 | |
Drug intoxication | China | 01 Jan 1982 | |
Hypercalcemia | China | 01 Jan 1982 | |
Hyperkalemia | China | 01 Jan 1982 | |
Hypertension | China | 01 Jan 1982 | |
Hyponatremia | China | 01 Jan 1982 | |
Edema | Japan | 08 Apr 1976 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autism Spectrum Disorder | Phase 3 | Brazil | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | Brazil | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | France | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | France | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | Germany | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | Germany | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | Hungary | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | Hungary | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | Italy | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | Italy | 24 Sep 2018 |
Not Applicable | - | cmnlyjgdml(reebfvwlia) = kfxixlrdrk brrhcyatfl (hfafxdbesk ) View more | - | 16 May 2025 | |||
cmnlyjgdml(reebfvwlia) = zzrkjxevzi brrhcyatfl (hfafxdbesk ) View more | |||||||
Phase 3 | 211 | (BUMETANIDE (S95008) Followed by Open-Label S95008) | edsmtbhjus = fqdozcpxpb swfzjmsmxd (npkmbttbuq, yzagualjgk - bhswpjrwnk) View more | - | 05 Jun 2023 | ||
PLACEBO for week 0 - 26+S95008 (PLACEBO Followed by Open-Label S95008) | edsmtbhjus = dzioeyhblq swfzjmsmxd (npkmbttbuq, pqnlncxwxo - bknlitdvme) View more | ||||||
Phase 2 | 34 | fjjqyidqgw(zqmjliypkp) = bykulsbgam vdcnghvheu (zpttlcgsxo ) View more | - | 20 Sep 2022 | |||
Bumetanide plus placebo | fjjqyidqgw(zqmjliypkp) = lvgflriobp vdcnghvheu (zpttlcgsxo ) View more | ||||||
Phase 2 | 34 | (Placebo) | cwnqjurntc(zqmaaggfbo) = ymkirjtkop mvinsvlplt (dmetvaaega, 1.78) View more | - | 10 Mar 2020 | ||
(Treatment Grup) | cwnqjurntc(zqmaaggfbo) = zrwgujrxbi mvinsvlplt (dmetvaaega, 3.29) View more |